Jun 12, 2008 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, a novel, oral platinum compound. The patent is entitled, "Satraplatin for treating resistant or refractory tumors" and covers certain uses of satraplatin related to the treatment of a cancer or tumor resistant or refractory to a taxane, including docetaxel (Taxotere(R)) and paclitaxel (Taxol(R)). The term of the patent extends up to 2025.
The details can be read here.
No comments:
Post a Comment